<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993863</url>
  </required_header>
  <id_info>
    <org_study_id>33CL230</org_study_id>
    <secondary_id>33CL230</secondary_id>
    <nct_id>NCT00993863</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction</brief_title>
  <official_title>A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859
      compared with placebo and an active control (ibuprofen) in subjects with acute dental pain
      after third molar extraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total pain relief 0-4 hours after study medication</measure>
    <time_frame>4 hours after study medication</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADL5859 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADL5859 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADL5859 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADL5859 30 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>ADL5859 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADL5859 100 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>ADL5859 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADL5859 200 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>ADL5859 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen 400 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>ibuprofen 400 mg</arm_group_label>
    <other_name>Advil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  have 2 or more 3rd molars requiring extraction, including at least 1 partially or
             completely bone-impacted mandibular molar

          -  experience moderate to severe pain intensity as measured by the Numeric Pain Rating
             Scale (NPRS) (score â‰¥ 5) within 6 hours after surgery

          -  for male subjects, be surgically sterile or agree to use an appropriate method of
             contraception or have a sexual partner who is surgically sterile or using an
             insertable, injectable, transdermal, or combination oral contraceptive

          -  for female subjects, be using contraceptives, be postmenopausal, or have undergone
             hysterectomy or tubal ligation

          -  be able to take oral study medications

        Key Exclusion Criteria:

          -  have positive results either on the urine screening tests for opiates,
             tetrahydrocannabinol,cocaine, amphetamines, barbiturates, benzodiazepines,
             phencyclidine, or propoxyphene or on the alcohol breathalyzer test

          -  have a history of alcoholism or drug addiction or abuse within 5 years before dosing
             with study medication

          -  have a history of chronic use (defined as daily use for &gt; 2 weeks) of
             glucocorticoids,nonsteroidal anti-inflammatory drugs, or opiates for any condition
             within 6 months of study medication administration

          -  have a known allergy or history of significant reaction to any of the known treatment
             medications (ADL5859-like compounds or ibuprofen) or rescue pain medication
             (acetaminophen)

          -  have significant renal or hepatic disease, as indicated by clinical laboratory
             assessment

          -  have a known history of epilepsy or seizure disorder, including history of febrile
             seizure, or any other medical or psychiatric condition that, in the judgment of the
             investigator, would put the subject at risk while in the study, could influence the
             results of the study, or could negatively affect the subject's ability to participate
             in the study

          -  have a history or evidence of orthostatic hypotension at screening have a history of
             significant head trauma (head injury with loss of consciousness)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SCIREX Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <name_title>Senior Medical Director, Clinical Research</name_title>
    <organization>Adolor Corporation</organization>
  </responsible_party>
  <keyword>delta opioid agonist</keyword>
  <keyword>dental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

